Von Willebrand factor: Biological function and molecular defects

Pediatric Hematology and Oncology

Volumn 14, Issue 6, 1997, Pages 499-512

  Perutelli, Paolo ^a   Biglino, Paola ^a   Mori, Pier Giorgio ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Factor VIII; Hemostasis; Platelet membrane glycoproteins; von Willebrand disease; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN; HEPARIN; MEMBRANE RECEPTOR; VON WILLEBRAND FACTOR;

BINDING SITE; BLEEDING; BLOOD CLOTTING; DISEASE CLASSIFICATION; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR BIOLOGY; PROTEIN BINDING; REVIEW; SHEAR STRESS; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VON WILLEBRAND DISEASE;

EID: 0030720815     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019709030907     Document Type: Review

References (68)

1. Fowler WE, Fretto LJ. Electron microscopy of von Willebrand factor. In: Zimmerman TS, Ruggeri ZM, eds. Coagulation and Bleeding Disorders. The Role of Factor VIII and von Willebrand Factor. New York: Marcel Dekker; 1989:181-193.
2. Bridges AB, McLaren M, Scott NA, Pringle TH, McNeill GP, Belch JJ. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. Br Heart J. 1993;69:121-124.
3. Mazurier C, Daffos F, Forestier F. Electrophoretic and functional characteristics of von Willebrand factor in human fetal plasma. Br J Haematol. 1992;81:263-270.
4. Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem. 1995;270: 23352-23361.
5. Pareti FI, Cattaneo M, Carpinelli L, et al. Evaluation of the abnormal platelet function in von Willebrand disease by the blood filtration test. Thromb Haemost. 1996;75:460-468.
6. Vlot AJ, Koppelman SJ, Meijers JCM, et al. Kinetics of factor VIII - von Willebrand factor association. Blood. 1996;87:1809-1816.
7. Mancuso DJ, Tuley EA, Westfield LA, et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry. 1991;30:253-269.
8. Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost. 1992; 67:594-599
9. Dong Z, Thoma RS, Crimmins DL, DeCourt DW, Tuley EA, Sadler JE. Disulfide bonds required to assemble functional von Willebrand factor multimers. J Biol Chem. 1994;269:6753-6758.
10. Rehemtulla A, Kaufman RJ. Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzyme. Blood. 1992;79:2349-2355.
11. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;83:3536-3544.
12. Journet AM, Saffaripour S, Cramer EM, Tenza D, Wagner DD. von Willebrand factor storage requires intact prosequence cleavage site Eur J Cell Biol. 1993;60:31-41.
13. Federici AB, Bader R, Pagani S, Colibretti ML, DeMarco L, Mannucci PM. Binding of von Willebrand factor to glycoproteins Ib and IIb-IIIa complex: affinity is related to multimeric size. Br J Haematol. 1989;73:93-99.
14. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235-4244.
15. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994;83:2171-2179.
16. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the costituent subunits. J Clin Invest. 1991;88:774-782.
17. Denis C, Baruch D, Kielty CM, Ajzenberg N, Christophe O, Meyer D. Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. Arterioscler Thromb. 1993;13:398-406.
18. Pietu G, Ribba AS, Cherel G, et al. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries. Thromb Haemost. 1994;71:788-792.
19. Lankhof H, van Hoeij M, Schiphorst ME, et al. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost. 1996;75.950-958.
20. Sobel M, McNeill PM, Carlson P, et al. Heparin inhibition of von Willebrand factor - dependent platelet function in vitro and in vivo. J Clin Invest. 1991;87:1787-1793.
21. Matsuita T, Sun H, Sadler JE. Identification of amino acid residues essential for human von Willebrand factor binding to heparin. Blood. 1995;86(suppl 1):449a.
22. Berndt MC, Ward CM, Booth WJ, Castaldi PA, Mazurov AV, Andrews RK. Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin. Biochemistry. 1992;31:11144-11151.
23. Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem. 1995;270:13406-13414.
24. Perutelli P, Mori PG. The human platelet membrane glycoprotein IIb/IIIa complex: a multi functional adhesion receptor. Haematologica. 1992;77:162-168.
25. Cooney KA, Ginsburg D. Comparative analysis of type 2B von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets. Blood. 1996;87:2322-2328.
26. Siguret V, Ribba AS, Christophe O, et al. Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695. Thromb Haemost. 1996;76:453-459.
27. Ikeda Y, Handa M, Kamata T, et al. Transmembrane calcium influx associated with von Willebrand factor binding to GPIb in the initiation of shear-induced platelet aggregation. Thromb Haemost. 1993;69:496-502.
28. Hoylaerts MF, Nuyts K, Peerlinck K, Deckmynh H, Vermylen J. Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin. Biochem J. 1995;306:453-463.
29. Christophe O, Rouault C, Obert B, Pietu G, Meyer D, Girma JP. A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulfide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease. Br J Haematol. 1995;90:195-203.
30. Fujimura Y, Kawasaki T, Titani K. Snake venom proteins modulating the interaction between von Willebrand factor and platelet glycoprotein Ib. Thromb Haemost. 1996;76:633-639.
31. Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost. 1993;69:177-184.
32. Christophe O, Ribba AS, Baruch D, et al. Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor. Blood. 1994;83:3553-3561.
33. Nesbitt IM, Goodeve AC, Guilliatt AM, Makris M, Preston FE, Peake IR. Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques. Thromb Haemost. 1996;75:959-964.
34. Nesbitt IM, Goodeve AC, Preston FE, Peake IR. von Willebrand factor/factor VIII binding is not affected by the Arg89Gln polymorphism in von Willebrand factor. Thromb Haemost. 1996;76:813-821.
35. von Willebrand EA. Hereditāri pseudohemofili. Fin Lakaresallsk Handl. 1926;68:87-112.
36. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost. 1994;71:520-525.
37. Ruggeri ZM. Pathogenesis and classification of von Willebrand disease. Haemostasis. 1994;24:267-275.
38. Lusher JM. Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease. Haemostasis. 1994;24:276-284.
39. Zhang ZP, Blomback M, Egberg N, Falk G, Anvret M. Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics. 1994;21:188-193.
40. Ngo KY, Trifard Glotz V, Koziol JA, et al. Homozygous and heterozygous deletions of the von Willebrand disease. Proc Natl Acad Sci USA. 1988;85:2753-2757.
41. Peake IR, Liddell MB, Moodie P, et al. Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood. 1990;75:654-661.
42. Pezzetti L, Redaelli R, Caimi TM, Cattaneo D, Baudo F, DeCataldo F. The multimeric pattern of von Willebrand's factor (vWf) can be demonstrated also in the severe form of the disease. Int J Hematol. 1992;55:88-91.
43. DeMarco L, Mazzuccato M, DeRoia D, et al. Distinct abnormalities in the interaction of purified type IIA and type IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa. J Clin Invest. 1990;86:785-792.
44. Fressinaud E, Sakariassen KS, Rothschild C, Baumgartner HR, Meyer D. Shear rate - dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A. Blood. 1992;80:988-994.
45. Donner M, Kristoffersson AC, Berntorp E, et al. Two new candidate mutations in type ILA von Willebrand disease (Arg834 → Gly, Gly846 → Arg) and one polymorphism (Tyr821→Cys) in the A2 region of the von Willebrand factor. Eur J Haematol. 1993;51:38-44.
46. Gaucher C, Hanss M, Dechavanne M, Mazurier C. Substitution of cysteine for phenylalanine 751 in mature von Willebrand factor is a novel candidate mutation in a family with type IIA von Willebrand disease. Br J Haematol. 1993;83:94-99.
47. Inbal A, Eglender T, Kornbrot N, et al. Identification of three candidate mutations causing type IIA von Willebrand disease using a rapid, nonradioactive, allele-specific hybridization method. Blood. 1993;82:830-836.
48. Lavergne JM, de Paillette L, Bahnak BR, et al. Defects in type IIA von Willebrand disease. A cysteine 509 to arginine substitution in the mature von Willebrand factor disrupts a disulphide loop involved in the interaction with platelet glycoprotein Ib-IX. Br J Haematol. 1992;82:66-72.
49. Hagiwara T, Inaba H, Yoshida S, Nagaizumi K, Hanabusa H, Fukutake K. A novel mutation Gly 1672→Arg in type 2A and a homozygous mutation in type 2B von Willebrand disease. Thromb Haemost. 1996;76:253-257.
50. Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem. 1992;267:4424-4430.
51. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA. 1990;87:6306-6310.
52. Cooney KA, Lyons SE, Ginsburg D. Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets. Proc Natl Acad Sci USA, 1992;89:2869-2872.
53. Hilbert L, Gaucher C, deRomeuf C, Horellou MH, Vink T, Mazurier C. Leu 697→Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood. 1994;83: 1542-1550.
54. Rabinowitz I, Randi AM, Shindler KS, Tuley EA, Rustagi PK, Sadler JE. Type IIB mutation His 505 → Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem. 1993;268:20497-20501
55. Wood NG, Standen GR, Bowen DJ, et al. UHG-based mutation screening m type 2B von Willebrand's disease: detection of a candidate mutation Ser547Phe. Thromb Haemostas. 1996;75:363-367.
56. Rabinowitz I, Tuley EA, Mancuso DJ, et al von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc Natl Acad Sci USA. 1992;89:9846-9849.
57. Siguret V, Lavergne JM, Cherel G, et al. A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWD. Hum Genet. 1994;93:95-102.
58. Schneppenheim R, Budde U, Krey S, et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost. 1996; 76:598-602.
59. Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand Factor and the diagnosis of type 2N von Willebrand disease. Results of an international survey. Thromb Haemost. 1996;76:270-274.
60. Kroner PA, Foster PA, Fahs SA, Montgomery RR. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor Blood. 1996;87:1013-1021.
61. Miller JL. Platelet-type von Willebrand disease. Thromb Haemost. 1996;75:265-269.
62. Miller JL, Cunningham D, Lyle VA, Finch CN. Mutation in the gene encoding the a chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Sci Acad USA. 1991;88:4761-4765.
63. Takahashi H, Murata M, Moriki T, et al. Substitution of Val for Met at residue 239 of platelet glycoprotein Ibα in Japanese patients with platelet-type von Willebrand disease. Blood. 1995;85:727-733.
64. Sadler JE. von Willebrand disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone; 1994:843-857.
65. Rodeghiero F, Castaman G, Tosetto A. von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type I von Willebrand disease. Results based on an epidemiological investigation. Thromb Haemost. 1990;64:349-352.
66. Quiroga T, Tagle R, Pereire J, Mezzano D. Sex-related difference in plasma von Willebrand factor (vWF:Ag and vWF:RiCof) levels in adolescents. Thromb Haemost. 1994;71:800-801.
67. Sadler JE, Ginsburg D. A database of polymorphisms in the von Willebrand factor gene and pseudogene. Thromb Haemost. 1993;69:185-191.
68. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood. 1992:79:3130-3137.